FDA Hypocrisy: Drug Trials, Black Box Warnings & Oversight

Introduction: The FDA's Moral Accountability

How can one trust a daily supplement, hormone replacement, or pharmaceutical intervention when political or pharmaceutical agendas may influence its approval? There is a pressing need for the Food and Drug Administration (FDA) to realign its moral objectivity. The agency has held American population health and wellbeing in its hands since its inception, yet it increasingly uses media and patient-provider channels for public relations purposes rather than genuine transparency. It has become apparent that clinical trials, responses to adverse prescription reactions, and endorsements of non-regulated foods and medications have been conducted in service of special interests and monetary gains backed by large businesses and pharmaceutical companies.

This paper reviews previous literature regarding the FDA's problematic inconsistencies, its oversight of subsidiaries, authorization processes, and the implementation of food and drug policies. Additional areas of focus include Black box warning indications, the expediting of drug trials, and the FDA's exercise of power over what data — submitted to the agency by manufacturers for approval — is actually disclosed to the public.

Clinical Trial Evidence and Inconsistencies

Current clinical medication trials are riddled with ethical problems. Research shows that a medication effective for one control group may not produce the same effect — or may produce an entirely different effect — in other populations (Campbell et al., 2018; Chang et al., 2015; Llamas, 2020; Lupkin, 2017; Mulinari & Davis, 2019). For example, limited literature associates Metformin use with a reduced prevalence of dementia, but specifically among individuals who use it to manage diabetes. People without diabetes have not demonstrated the same benefit, and prior research does not support such an application.

A significant reduction in dementia risk was tested and established only within the diabetic population, corroborating the finding that Metformin's use for dementia prevention is not supported for those who do not suffer from diabetes. Because Metformin's benefit in this context rests on a single clinical trial involving Alzheimer's and diabetic patients, its indication for creating a reduced risk of dementia is based on an extremely narrow evidentiary foundation. It is therefore reasonable to conclude that Metformin should not be recommended for non-diabetic patients as a treatment for dementia.

Further investigation is required before the FDA can confidently prescribe Metformin across populations, as demographic, environmental, and social factors may influence how the medicine works for different individuals. Without such certainty, the FDA should exercise caution about circulating Metformin among those without diabetes, since certain studies in this category found worse cognitive performance in Metformin users after adjusting for vitamin B12 levels (Campbell et al., 2018).

It has become increasingly evident that the FDA has overextended its authority (Chang et al., 2015; Haffajee & Mello, 2017; Llamas, 2020; Reuters, 2019; Sobel, Madigan, & Wang, 2017). Research clearly indicates that the FDA modifies submitted data and that its published reports present substantially different information to the public (Chang et al., 2015). Manufacturers of new devices or medicines submit their relevant findings to the FDA for approval, yet the agency's published reports diverge from what was originally submitted. Data on fatalities, safety, and effectiveness have been altered, offering a misleading picture to a health industry that places enormous reliance on FDA approvals.

FDA Data Manipulation and Selective Reporting

Unfavorable results often remain unpublished in peer-reviewed journals, leaving both medical professionals and the general public unaware of significant safety concerns. When researchers compared manufacturers' publication requests against the number of publications the FDA actually produced, the contrast was stark. In some cases, the FDA failed to contact manufacturers with updates or notifications regarding device publications, and the data that eventually emerged appeared altered from the original trial submissions. It appears that the FDA selectively decides which data are exposed to the public and which are not. Summaries and declarations in available publications have been transformed, while certain restricted portions remain invisible to the public and medical specialists alike.

This pattern suggests that the FDA withholds data it does not want subjected to critical peer analysis. Long delays have been observed in this respect — cardiovascular trial results, for instance, remained unknown for unexpectedly extended periods. A notable example of the FDA's broader overreach involves the pharmaceutical industry's liability in the opioid epidemic, where regulatory decisions served financial rather than public health interests (Haffajee & Mello, 2017).

The Black box warning has come under scrutiny as a mechanism for flagging medications with the potential to provoke or risk death (Chang et al., 2015; Llamas, 2020; Lupkin, 2017; Sobel, Madigan, & Wang, 2017; Steffen et al., 2020; Verhaegh et al., 2016). The Trump administration pursued a policy of expediting the drug approval process, but these decisions produced consequences that forced the FDA to reconsider its actions in the interest of public health safety. On average, drug approvals had previously taken 4.2 years; under the faster approval process, more serious problems were observed specifically in psychiatric and biologic drugs (Lupkin, 2017).

Conclusion: The Case for Reform and Vigilance

Even after drugs have been on the market for a few years, expedited theoretical drug trials should be required for indications of Black box warnings, especially in times of pandemic — such as Covid-19 — when vaccinations are critical for decreasing mortality rates. The drug-development cycle is typically lengthy; the 4.2-year average FDA approval timeline reflects the scope of proactive, collaborative, and vigilant testing needed to safely monitor drugs before widespread use. Even when drugs have been available for several years, Black box warnings remain mandatory to prevent the adverse effects of expedited drugs from manifesting at any stage of a patient's life and imposing further costs on the healthcare economy.